交通医学
交通醫學
교통의학
Medical Journal of Communications
2015年
5期
443-446
,共4页
甲基化%DLC-1%肝细胞性肝癌%预后
甲基化%DLC-1%肝細胞性肝癌%預後
갑기화%DLC-1%간세포성간암%예후
methylation%DLC-1%hepatocellular carcinoma%prognosis
目的:研究肝细胞性肝癌患者血浆DLC-1甲基化状态,研究其与各临床相关因素的关系及对肝细胞性肝癌患者预后的意义.方法: 采用甲基化特异性PCR法检测肝细胞性肝癌患者和健康人群血浆中提取DNA的DLC-1甲基化状态,结合临床特征(性别、年龄、肝硬化、AFP水平、HbsAg及临床分期),分析DLC-1甲基化状态与肝细胞性肝癌患者复发转移和预后的关系.结果:96例肝细胞性肝癌患者血浆中DLC-1甲基化阳性率为30.2%,对照健康组无甲基化,差异有统计学意义(P<0.05).肝细胞性肝癌患者血浆DLC-1甲基化状况与性别、年龄、抗-HBV、肝硬化无相关性(P>0.05),与HBsAg、肿瘤大小、淋巴结转移及TNM分期相关(P<0.05).DLC-1甲基化阳性组较阴性组转移复发率高,存活率较甲基化阴性组低.结论:DLC-1基因甲基化状态与肝细胞性肝癌发生发展及预后密切相关,对肝细胞性肝癌复发转移预测具有重要的价值,有望成为评估肝细胞性肝癌预后的有效指标.
目的:研究肝細胞性肝癌患者血漿DLC-1甲基化狀態,研究其與各臨床相關因素的關繫及對肝細胞性肝癌患者預後的意義.方法: 採用甲基化特異性PCR法檢測肝細胞性肝癌患者和健康人群血漿中提取DNA的DLC-1甲基化狀態,結閤臨床特徵(性彆、年齡、肝硬化、AFP水平、HbsAg及臨床分期),分析DLC-1甲基化狀態與肝細胞性肝癌患者複髮轉移和預後的關繫.結果:96例肝細胞性肝癌患者血漿中DLC-1甲基化暘性率為30.2%,對照健康組無甲基化,差異有統計學意義(P<0.05).肝細胞性肝癌患者血漿DLC-1甲基化狀況與性彆、年齡、抗-HBV、肝硬化無相關性(P>0.05),與HBsAg、腫瘤大小、淋巴結轉移及TNM分期相關(P<0.05).DLC-1甲基化暘性組較陰性組轉移複髮率高,存活率較甲基化陰性組低.結論:DLC-1基因甲基化狀態與肝細胞性肝癌髮生髮展及預後密切相關,對肝細胞性肝癌複髮轉移預測具有重要的價值,有望成為評估肝細胞性肝癌預後的有效指標.
목적:연구간세포성간암환자혈장DLC-1갑기화상태,연구기여각림상상관인소적관계급대간세포성간암환자예후적의의.방법: 채용갑기화특이성PCR법검측간세포성간암환자화건강인군혈장중제취DNA적DLC-1갑기화상태,결합림상특정(성별、년령、간경화、AFP수평、HbsAg급림상분기),분석DLC-1갑기화상태여간세포성간암환자복발전이화예후적관계.결과:96례간세포성간암환자혈장중DLC-1갑기화양성솔위30.2%,대조건강조무갑기화,차이유통계학의의(P<0.05).간세포성간암환자혈장DLC-1갑기화상황여성별、년령、항-HBV、간경화무상관성(P>0.05),여HBsAg、종류대소、림파결전이급TNM분기상관(P<0.05).DLC-1갑기화양성조교음성조전이복발솔고,존활솔교갑기화음성조저.결론:DLC-1기인갑기화상태여간세포성간암발생발전급예후밀절상관,대간세포성간암복발전이예측구유중요적개치,유망성위평고간세포성간암예후적유효지표.
Objectives:To analyze the relationship between the promoter region DLC-1 DNA methylation status and the characteristics in hepatocellular cancer,and explore the role of DLC-1 DNA methylation in the occurrence and metastasis of hepatocellular cancer. Methods:96 cases of hepatocellular cancer specimens were selected,the methylation specific-PCR (MSP) was used to detect the tumor suppressor gene DLC-1 methylation in the above-mentioned tissues. To explore their roles of them in the occurrence and development of hepatocellular cancer, and the relationship associated with the clinical relevant factors. And to further analyze of the relationship between the promoter region of DLC-1 methylation status and the characteristics of methylation of the genome-wide in hepatocellular cancer.Disscussion the relationship between the methylation status with clinicopathologic factors (sex, age, AFP, differentiation degree, clinical stage,) and progression-free survival (PFS) as well as overall survival (OS) was analyzed. Results:The methylation status of DLC-1 in plasma of hepatocellular cancer patients was 30.1%. There were no correlations among the DLC-1 methylation status in hepatocellular cancer plasma and the patient's sex, age, cirrhosis and anti-HBV (P>0.05), but it was correlated with degrees of differentiation TNM staging. Multivariate analysis indicated that besides the tumor size, the methylation status is also an independent risk factor influencing recurrence, also independently correlated with TTP and OS in hepatic patients. Conclusions:DLC-1 methylation shows great importance in the field of judging the prognosis. Tumor suppressor gene DLC-1 methylation is an early molecular index of hepatocellular cancer.
